Can a new drug combo flush out hidden HIV?
NCT ID NCT07053384
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This early-stage study tests whether adding an experimental drug (VH3810109) with or without another drug (fostemsavir) to standard HIV therapy can reduce the hidden viral reservoir in people living with HIV. About 107 adults, either new to treatment or already on stable therapy, will participate. The goal is to see if these combinations can lower the amount of inactive HIV hiding in cells, which is a key step toward better long-term control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Bakersfield, California, 93301, United States
-
GSK Investigational Site
San Diego, California, 92103, United States
-
GSK Investigational Site
Ft. Pierce, Florida, 34982, United States
-
GSK Investigational Site
Orlando, Florida, 32803, United States
-
GSK Investigational Site
Chicago, Illinois, 60611, United States
-
GSK Investigational Site
Kansas City, Missouri, 64111, United States
-
GSK Investigational Site
St Louis, Missouri, 63110, United States
-
GSK Investigational Site
New York, New York, 10032, United States
-
GSK Investigational Site
Cincinnati, Ohio, 45267, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19104, United States
-
GSK Investigational Site
Pittsburgh, Pennsylvania, 15213, United States
-
GSK Investigational Site
Dallas, Texas, 75208, United States
-
GSK Investigational Site
Dallas, Texas, 75246, United States
-
GSK Investigational Site
Brussels, 1000, Belgium
-
GSK Investigational Site
Ghent, 9000, Belgium
-
GSK Investigational Site
Aarhus, 8200, Denmark
-
GSK Investigational Site
Hvidovre, 2650, Denmark
-
GSK Investigational Site
Rotterdam, 3015 GD, Netherlands
-
GSK Investigational Site
Barcelona, 08003, Spain
-
GSK Investigational Site
Barcelona, 08026, Spain
-
GSK Investigational Site
Barcelona, 08035, Spain
-
GSK Investigational Site
Barcelona, 08036, Spain
-
GSK Investigational Site
Barcelona, 08916, Spain
-
GSK Investigational Site
Barcelona, 8907, Spain
-
GSK Investigational Site
Córdoba, 14004, Spain
-
GSK Investigational Site
La Laguna Santa Cruz, 38320, Spain
-
GSK Investigational Site
Madrid, 28020, Spain
-
GSK Investigational Site
Madrid, 28031, Spain
-
GSK Investigational Site
Madrid, 28034, Spain
-
GSK Investigational Site
Madrid, 28040, Spain
-
GSK Investigational Site
Madrid, 28041, Spain
-
GSK Investigational Site
Madrid, 28046, Spain
-
GSK Investigational Site
Madrid, 28224, Spain
-
GSK Investigational Site
Palma de Mallorca, 07120, Spain
-
GSK Investigational Site
Palma de Mallorca, 7198, Spain
-
GSK Investigational Site
Seville, 41013, Spain
-
GSK Investigational Site
Valencia, 46014, Spain
-
GSK Investigational Site
Valencia, 46026, Spain
-
GSK Investigational Site
London, NW3 2QG, United Kingdom
-
GSK Investigational Site
London, SE1 7EH, United Kingdom
-
GSK Investigational Site
London, W2 1NY, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop anal lesions from becoming cancer?
- Can resilience defeat HIV stigma? a new study investigates
- Peer support may curb HIV stigma and stress in vietnamese gay men
- A pharmacist's touch: could structured medication reviews boost HIV treatment success?
- A new Fast-Track HIV care model aims to Re-Engage those lost to care
- Can a smartphone app curb HIV risk in south Korea's young gay men?